Health Care • Biotechnology: Pharmaceutical Preparations
$28.04 ▼ -0.82
(-2.84%)
MKT CAP: $3.62B • VOL: 1.16M
52W L $11 52W H $41
ROARABLE / RQD
D- • 39/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$24
MEDIAN
$31
MEAN
$32
HIGH
$38
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AMLX TAPE
AMLX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $33.93 | $32.25 | 2025-02-14 | $25.52 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $35.33 | $33.09 | 2025-02-06 | $26.36 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $31.97 | $30.84 | 2025-01-29 | $26.92 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $28.60 | — | 2025-01-17 | $27.48 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $24.68 | $26.64 | 2025-01-09 | $24.96 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $33.37 | $29.16 | 2024-12-18 | $24.39 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $27.20 | $28.32 | 2024-12-04 | $26.08 | -4.3% | 48% | C |